The Board of Directors welcomes new Board Members Giovanni Cerutti and Luca Melindo who will support the company’s future growth
The Ordinary Shareholder’s Meeting of BetaGlue Technologies appointed the new Board of Directors: Colin Story, Giovanni Cerutti and Luca Melindo have been appointed Directors of the Company, while Diana Saraceni, Claudio Giuliano, Michel Therin are re-elected, as well as Riccardo Palmisano, who remains in office as Chairman.
The new Members of the Board appointed Colin Story as CEO of BetaGlue Technologies, who commented: “BetaGlue’s clinical development programmes hold great promise to significantly benefit patients and healthcare providers and I’m delighted to be appointed CEO at this very exciting stage in the company’s evolution. The talented team at BetaGlue, both past and present, have made tremendous progress and as a team we’ll be working hard to build on this foundation with a primary focus of bringing new and innovative targeted radiotherapy treatment options to cancer patients”.
Thanks to their strong experience and comprehensive knowledge of the industry, the newly appointed Board Members are yet another valuable addition that can strengthen BetaGlue’s Governing Body and will provide additional support to the Company’s future growth.
Profiles of the new Directors
Colin Story brings over 25 years of medical technology and Life Sciences industry experience. After graduating with a PhD in Molecular Biology, he started his career at Amersham plc (now GE Healthcare) where he headed a global commercial role with full P&L accountability. In 2005, he joined Isis Innovation, while in 2011, he was invited to join OrganOx as Operations Director. Dr Story co-founded OxSonics in 2013 and served as CEO from January 2014 through to January 2022. Under his leadership, a total of £25m was raised and OxSonics’ proprietary ‘SonoTran’ platform technology transitioned into clinical use. Dr Story also currently holds the position of Non-Executive Director of Hox Therapeutics, a biotechnology company focussed on the treatment of Prostate Cancer.
Giovanni Cerutti is Business Unit Head in Advanced Accelerator Applications (AAA), a Novartis Company. He has a wealth of experience as a seasoned Commercial Director in AAA Italy and former Country Business Manager Italyin GE HealthCare/Amersham, launching a loco-regional oncologic radiotherapy platform, and over 30 years of working experience in the pharmaceutical and healthcare industry. He boasts a proven track record in managing start-up branches, growing market share and profitability, with extensive experience in the investment world. At the companies where he has served, he has held roles in both the head offices and subsidiaries, and in different departments.
Luca Melindo has twenty years of experience in Private Equity and Venture Capital. He managed investment and divestment deals with significant returns on invested capital. He boasts a sound expertise in management control, corporate finance, M&A and management of corporate activities. He currently holds several corporate offices, also with operational powers, and works, as a consultant, with an investment fund operating in the biotech sector.